[go: up one dir, main page]

ATE230980T1 - Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden - Google Patents

Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden

Info

Publication number
ATE230980T1
ATE230980T1 AT94931991T AT94931991T ATE230980T1 AT E230980 T1 ATE230980 T1 AT E230980T1 AT 94931991 T AT94931991 T AT 94931991T AT 94931991 T AT94931991 T AT 94931991T AT E230980 T1 ATE230980 T1 AT E230980T1
Authority
AT
Austria
Prior art keywords
sustained release
metoprolol
hours
delivery
release formulations
Prior art date
Application number
AT94931991T
Other languages
English (en)
Inventor
Anand R Baichwal
John N Staniforth
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Application granted granted Critical
Publication of ATE230980T1 publication Critical patent/ATE230980T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94931991T 1993-11-12 1994-10-19 Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden ATE230980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/151,272 US5399358A (en) 1993-11-12 1993-11-12 Sustained release formulations for 24 hour release of metroprolol
PCT/US1994/012139 WO1995013055A1 (en) 1993-11-12 1994-10-19 Sustained release formulations for 24 hour release of metoprolol

Publications (1)

Publication Number Publication Date
ATE230980T1 true ATE230980T1 (de) 2003-02-15

Family

ID=22538025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931991T ATE230980T1 (de) 1993-11-12 1994-10-19 Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden

Country Status (16)

Country Link
US (1) US5399358A (de)
EP (1) EP0730444B1 (de)
JP (1) JP2832248B2 (de)
KR (1) KR100197841B1 (de)
CN (1) CN1198596C (de)
AT (1) ATE230980T1 (de)
AU (1) AU675370B2 (de)
CA (1) CA2171844C (de)
DE (1) DE69432025T2 (de)
DK (1) DK0730444T3 (de)
ES (1) ES2191034T3 (de)
FI (1) FI116450B (de)
HU (1) HU223612B1 (de)
IL (1) IL111400A (de)
TW (1) TW314469B (de)
WO (1) WO1995013055A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
DK0706377T3 (da) * 1994-04-25 2002-04-02 Mendell Co Inc Edward Excipiens med forlænget frigivelse
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
CN1228043C (zh) * 1999-09-30 2005-11-23 爱德华·孟岱尔股份有限公司 用于高溶解度药物的缓释基质
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
PL208484B1 (pl) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu
BR0205721A (pt) * 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
JP2005523876A (ja) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
CA2479252A1 (en) * 2002-03-22 2003-10-02 Cilag Ag Sustained release formulation of tramadol
MXPA04009701A (es) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Formulaciones de metoprolol de liberacion sostenida.
CA2494281A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US6936574B2 (en) * 2002-08-30 2005-08-30 Halliburton Energy Services, Inc. Process for controlling gas migration during well cementing
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
KR100782918B1 (ko) * 2003-09-19 2007-12-07 펜웨스트 파머슈티칼즈 컴파니 지연 방출성 제형
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
JP2007522203A (ja) * 2004-02-11 2007-08-09 アスファーマ・リミテッド 時間療法用組成物とそれらの使用方法
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US20070053983A1 (en) * 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
JPWO2008041553A1 (ja) * 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20080085304A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
EP2448406B1 (de) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
EP2255791B1 (de) * 2009-04-03 2011-11-16 Zaklady Farmaceutyczne Polpharma SA Pharmazeutische Zusammensetzung mit verlängerter Freisetzung mit Metoprololsuccinat
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
EP3316862A4 (de) 2015-07-02 2019-02-06 University of Louisville Research Foundation, Inc. Aus essbarer pflanze erlangte mikrovesikelzusammensetzungen zur abgabe von mirna und verfahren zur behandlung von krebs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5081154A (en) * 1984-01-10 1992-01-14 Aktiebolaget Hassle Metoprolol succinate
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4857331A (en) * 1988-03-31 1989-08-15 Warner-Lambert Company Sugarless pectin delivery system
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs

Also Published As

Publication number Publication date
AU675370B2 (en) 1997-01-30
TW314469B (de) 1997-09-01
KR100197841B1 (ko) 1999-06-15
EP0730444B1 (de) 2003-01-15
HU9601008D0 (en) 1996-06-28
DE69432025T2 (de) 2003-10-16
CN1109328A (zh) 1995-10-04
CA2171844A1 (en) 1995-05-18
JP2832248B2 (ja) 1998-12-09
IL111400A (en) 1999-03-12
HU223612B1 (hu) 2004-10-28
FI961996L (fi) 1996-05-29
ES2191034T3 (es) 2003-09-01
FI961996A0 (fi) 1996-05-10
WO1995013055A1 (en) 1995-05-18
CN1198596C (zh) 2005-04-27
DK0730444T3 (da) 2003-04-14
AU8087594A (en) 1995-05-29
CA2171844C (en) 2000-05-30
IL111400A0 (en) 1994-12-29
EP0730444A4 (de) 1996-11-06
FI116450B (fi) 2005-11-30
EP0730444A1 (de) 1996-09-11
HUT75881A (en) 1997-05-28
US5399358A (en) 1995-03-21
JPH08511807A (ja) 1996-12-10
DE69432025D1 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
ATE230980T1 (de) Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden
DE69638364D1 (de) Formulierungen mit kontrollierter abgabe (albuterol)
EP0700284A4 (de) Oxybutyninformulierungen mit gesteuerter freisetzung
DE69523438D1 (de) Orale metoprolol-dosisform des typs "einmal täglich"
ES2094359T3 (es) Formulaciones farmaceuticas de proteinas osteogenicas.
ATE131039T1 (de) Arzneimittel in gelform in einem spender.
NZ264487A (en) Tetracycline based prodrug conjugate, pharmaceutical compositions thereof
ATE85213T1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
GB9112495D0 (en) Improved formulations of acetazolamide
CA2003981A1 (en) Pharmaceutical compositions and use thereof in the treatment of psoriasis
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
ZA943648B (en) Medicament aerosol formulation based on fusafungine a process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0730444

Country of ref document: EP

REN Ceased due to non-payment of the annual fee